The long-term evolution of chronic hepatitis B acquired in childhood

J Gastrointestin Liver Dis. 2009 Dec;18(4):433-8.

Abstract

The AIM of this study was to assess the long-term evolution of chronic hepatitis B acquired in childhood.

Methods: The study was carried out in 2007 - 2008 on a group of 77 adult patients who were diagnosed with chronic hepatitis B in childhood. The actual assessment included epidemiological, clinical, biological and virological data, ultrasound examination in all patients and liver histology in 3 patients.

Results: From the 77 patients, 69 were HBeAg positive and the other 8 patients were anti-HBe positive when the diagnosis was made in their childhood. Thirty-seven patients from the HBeAg positive group and 2 patients from the anti-HBe group had been treated in childhood with IFN-alpha and the other 38 patients remained untreated (32 patients with HBeAg positive and 6 patients anti-HBe positive). Overall, 78.26% seroconverted to anti-HBe (87.50% untreated and 70.27% of patients treated with IFN). After a median follow-up period of 13 years, 36 patients from the HBeAg positive group (48.65% of treated patients and 56.25% of untreated ones) became inactive carriers. Seroconversion to anti-HBs, in the HBeAg positive group, occurred in 10.14% of cases (8.1% in treated patients) without statistical significance. Three patients from the whole group developed cirrhosis but none developed hepatocellular carcinoma.

Conclusion: The long-term outcome in our patients with CHB acquired in childhood did not differ between treated and untreated patients.

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use
  • Aspartate Aminotransferases / blood
  • Carrier State
  • Child
  • Child, Preschool
  • DNA, Viral / blood
  • Disease Progression
  • Female
  • Hepatitis B / genetics
  • Hepatitis B / immunology
  • Hepatitis B Antibodies / blood
  • Hepatitis B e Antigens / blood
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / epidemiology*
  • Humans
  • Infant
  • Interferons / therapeutic use
  • Liver / pathology
  • Liver / virology
  • Male
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B e Antigens
  • Interferons
  • Aspartate Aminotransferases
  • Alanine Transaminase